Valneva (VALN) Stock Price, News & Analysis

Company Overview

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Key Stats

• Today's Range: $7.00 to $7.39
• 50-Day Range: $4.31 to $8.33
• 52-Week Range: $3.62 to $9.50
• Volume: 20,330 shs
• Average Volume: 26,063 shs
• Market Capitalization: $574.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Valneva Stock Analysis - MarketRank™

Valneva scored higher than 48% of companies evaluated by MarketBeat, and ranked 564th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Valneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Valneva has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Valneva are expected to decrease in the coming year, from $0.13 to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Valneva is -54.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Valneva is -54.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Valneva has a P/B Ratio of 3.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Valneva has been sold short.

Short Interest Ratio / Days to Cover

Valneva has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Valneva has recently decreased by 84.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Valneva does not currently pay a dividend.

Dividend Growth

Valneva does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Valneva has been sold short.

Short Interest Ratio / Days to Cover

Valneva has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Valneva has recently decreased by 84.20%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.14

News Sentiment

Valneva has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Valneva this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for VALN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Valneva to their MarketBeat watchlist in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Valneva insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.39% of the stock of Valneva is held by institutions.

VALN Stock Analysis - Frequently Asked Questions

How have VALN shares performed this year?

Valneva's stock was trading at $4.37 at the start of the year. Since then, VALN shares have increased by 62.5% and is now trading at $7.10.
View the best growth stocks for 2025 here.

How were Valneva's earnings last quarter?

Valneva SE (NASDAQ:VALN) announced its quarterly earnings data on Thursday, March, 20th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.32. The business had revenue of $56.48 million for the quarter, compared to analyst estimates of $55.64 million. Valneva had a negative trailing twelve-month return on equity of 3.93% and a negative net margin of 4.35%.

When did Valneva IPO?

Valneva (VALN) raised $99 million in an initial public offering (IPO) on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO.

Who are Valneva's major shareholders?

Valneva's top institutional shareholders include Wells Fargo & Company MN (0.30%) and ABC Arbitrage SA (0.02%).

How do I buy shares of Valneva?

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Valneva own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Valneva investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VALN
• CIK: 1836564
• Web: valneva.com
• Phone: 33-2-28-07-37-10
• Fax: N/A
• Employees: 700
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $17.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +126.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 54.38
• P/E Growth: N/A
• Net Income: $-109,780,000.00
• Net Margins: -4.35%
• Pretax Margin: N/A
• Return on Equity: -3.93%
• Return on Assets: -1.42%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 2.78
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: $158.54 million
• Price / Sales: 3.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 3.54

Miscellaneous

• Outstanding Shares: 81,261,000
• Free Float: 69,145,000
• Market Cap: $574.52 million
• Optionable: Not Optionable
• Beta: 1.93